Across TCGA pan-cancer cohorts, CYCSP44 RNA differs between tumor and matched normal tissue in 2 of 18 cancer types tested, making tumor–normal expression one of CYCSP44’s most consistent transcriptional readouts.
The strongest signal is observed in lung adenocarcinoma (LUAD), where CYCSP44 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types CYCSP44 is over-expressed in tumor.
LUAD and BRCA are the cancer types where CYCSP44 tumor–normal differential expression is most reproducible.